JP2021512315A - 循環マイクロ粒子関連バイオマーカーを利用する子癇前症の早期予測および予防に関する方法 - Google Patents

循環マイクロ粒子関連バイオマーカーを利用する子癇前症の早期予測および予防に関する方法 Download PDF

Info

Publication number
JP2021512315A
JP2021512315A JP2020541680A JP2020541680A JP2021512315A JP 2021512315 A JP2021512315 A JP 2021512315A JP 2020541680 A JP2020541680 A JP 2020541680A JP 2020541680 A JP2020541680 A JP 2020541680A JP 2021512315 A JP2021512315 A JP 2021512315A
Authority
JP
Japan
Prior art keywords
biomarkers
eclampsia
human
protein
risk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020541680A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512315A5 (cg-RX-API-DMAC7.html
Inventor
ケビン・ピー・ローゼンブラット
トーマス・エフ・マッケルラス
ブライアン・ディ・ブローマン
ロバート・シー・ドス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nx Prenatal Inc
The Brigham and Women's Hospital Inc
NX Prenatal Inc
Original Assignee
Nx Prenatal Inc
The Brigham and Women's Hospital Inc
NX Prenatal Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nx Prenatal Inc, The Brigham and Women's Hospital Inc, NX Prenatal Inc filed Critical Nx Prenatal Inc
Publication of JP2021512315A publication Critical patent/JP2021512315A/ja
Publication of JP2021512315A5 publication Critical patent/JP2021512315A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G16B5/20—Probabilistic models
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Data Mining & Analysis (AREA)
  • Immunology (AREA)
  • Primary Health Care (AREA)
  • Databases & Information Systems (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Artificial Intelligence (AREA)
JP2020541680A 2018-01-31 2019-01-31 循環マイクロ粒子関連バイオマーカーを利用する子癇前症の早期予測および予防に関する方法 Pending JP2021512315A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862624626P 2018-01-31 2018-01-31
US62/624,626 2018-01-31
US201862641135P 2018-03-09 2018-03-09
US62/641,135 2018-03-09
PCT/US2019/016188 WO2019152741A1 (en) 2018-01-31 2019-01-31 Methods of early prediction and prevention of preeclampsia utilizing circulating microparticle-associated biomarkers

Publications (2)

Publication Number Publication Date
JP2021512315A true JP2021512315A (ja) 2021-05-13
JP2021512315A5 JP2021512315A5 (cg-RX-API-DMAC7.html) 2022-02-03

Family

ID=67479860

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020541680A Pending JP2021512315A (ja) 2018-01-31 2019-01-31 循環マイクロ粒子関連バイオマーカーを利用する子癇前症の早期予測および予防に関する方法

Country Status (7)

Country Link
US (2) US20210050112A1 (cg-RX-API-DMAC7.html)
EP (1) EP3746087A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021512315A (cg-RX-API-DMAC7.html)
KR (1) KR20200140796A (cg-RX-API-DMAC7.html)
CN (1) CN111918658A (cg-RX-API-DMAC7.html)
SG (1) SG11202007319SA (cg-RX-API-DMAC7.html)
WO (1) WO2019152741A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022015666A1 (en) * 2020-07-13 2022-01-20 Nx Prenatal Inc. Methods of assessing risk of and treating preeclampsia and subtypes thereof
US20250102482A1 (en) * 2021-11-11 2025-03-27 Nx Prenatal Inc. Methods of preparing and analyzing samples for biomarkers associated with placenta accreta
JP2025520311A (ja) * 2022-06-21 2025-07-03 ネオプレディクス アーゲー 妊娠高血圧腎症の進展予測方法およびシステム
CN117747110B (zh) * 2023-12-26 2024-11-15 南京鼓楼医院 基于母体因素和早期孕期生物标志物的子痫前期风险预测方法及系统
DE102024100425A1 (de) * 2024-01-09 2025-07-10 Charité - Universitätsmedizin Berlin Körperschaft des öffentlichen Rechts Verfahren und System zur Klassifikation eines Auftretens einer medizinischen Komplikation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100016173A1 (en) * 2008-01-30 2010-01-21 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
US20160025739A1 (en) * 2013-03-12 2016-01-28 Agency For Science, Technology And Research Pre-eclampsia biomarkers
WO2017096405A1 (en) * 2015-12-04 2017-06-08 Nx Prenatal Inc. Use of circulating microparticles to stratify risk of spontaneous preterm birth
US20170285041A1 (en) * 2014-09-02 2017-10-05 Wallac Oy Method for determining risk of pre-eclampsia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140186332A1 (en) * 2012-12-28 2014-07-03 NX Pharmagen Biomarkers of preterm birth
WO2015002845A1 (en) * 2013-07-01 2015-01-08 Anderson Cindy Biomarker for preeclampsia
RU2724013C2 (ru) * 2015-06-19 2020-06-18 Сера Прогностикс, Инк. Пары биологических маркеров для предсказания преждевременных родов
GB201511546D0 (en) * 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100016173A1 (en) * 2008-01-30 2010-01-21 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
US20160025739A1 (en) * 2013-03-12 2016-01-28 Agency For Science, Technology And Research Pre-eclampsia biomarkers
US20170285041A1 (en) * 2014-09-02 2017-10-05 Wallac Oy Method for determining risk of pre-eclampsia
WO2017096405A1 (en) * 2015-12-04 2017-06-08 Nx Prenatal Inc. Use of circulating microparticles to stratify risk of spontaneous preterm birth

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WU, F. ET AL.: "GPIbα reflects the development and progress of the patients with severe preeclampsia", INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, vol. 8, no. 4, JPN6022054100, 15 April 2015 (2015-04-15), pages 6039 - 6045, ISSN: 0005133032 *

Also Published As

Publication number Publication date
US20250329468A1 (en) 2025-10-23
EP3746087A4 (en) 2022-02-09
WO2019152741A1 (en) 2019-08-08
SG11202007319SA (en) 2020-08-28
US20210050112A1 (en) 2021-02-18
CN111918658A (zh) 2020-11-10
EP3746087A1 (en) 2020-12-09
KR20200140796A (ko) 2020-12-16

Similar Documents

Publication Publication Date Title
US11987846B2 (en) Biomarker pairs for predicting preterm birth
AU2022221445B2 (en) Biomarkers and methods for predicting preterm birth
US20250085293A1 (en) Biomarkers for predicting preterm birth due to preterm premature rupture of membranes (pprom) versus idiopathic spontaneous labor (ptl)
US20250329468A1 (en) Systems, devices, and methods for generating machine learning models and using the machine learning models for early prediction and prevention of preeclampsia
US20210057039A1 (en) Systems and methods of using machine learning analysis to stratify risk of spontaneous preterm birth
AU2011340630A1 (en) Biomarkers and parameters for hypertensive disorders of pregnancy
AU2018317902B2 (en) Pregnancy clock proteins for predicting due date and time to birth
US20240003907A1 (en) Methods of assessing risk of and treating preeclampsia and subtypes thereof
US20250102482A1 (en) Methods of preparing and analyzing samples for biomarkers associated with placenta accreta
HK40107594A (en) Biomarker pairs for predicting preterm birth
HK1254669B (en) Biomarker pairs for predicting preterm birth

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221220

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221223

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230308

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230822